Tesamorelin + Ipamorelin — Research Background

Tesamorelin is a synthetic analog of GHRH (Growth Hormone-Releasing Hormone) with an extended half-life compared to endogenous GHRH. Ipamorelin is a selective GH secretagogue and ghrelin receptor agonist. When combined, they stimulate GH release through two distinct pathways — GHRH receptor activation (Tesamorelin) and ghrelin receptor activation (Ipamorelin) — producing a synergistic GH pulse.

Clinical Applications

• Longevity Clinics: Core GH optimization protocol in comprehensive anti-aging programs. Frequently combined with NAD+ and BPC-157.
• TRT Clinics: Stacked with testosterone optimization protocols for body composition, recovery, and metabolic function research.
• Men's Health: GH optimization in age-related decline and metabolic health research protocols.
• Metabolic Research: Tesamorelin studied specifically in visceral adiposity and lipodystrophy research contexts.

Market Position

The GH secretagogue combination market is growing rapidly in European longevity and TRT clinics. The Tesamorelin + Ipamorelin stack has emerged as the preferred combination over older CJC-1295 + Ipamorelin protocols due to Tesamorelin's more selective GHRH-analog action and established research profile.